环氧合酶-2与结直肠癌的关系及以其为靶点的治疗进展  

Research Progress on Cyclooxygenase-2 in Colorectal Cancer and Its Application as a Therapeutic Target

作　　者：孙鹏[1] 权继传 关旭 郁雷[1] 刘正[2] 姜争 王贵玉[1] 王锡山[1,2] SUN Peng;QUAN Ji-chuan;GUAN Xu;YU Lei;LIU Zheng;JIANG Zheng;WANG Gui-yu;WANG Xi-shan(The Second Affiliated Hospital of Harbin Medical University,Harbin 150000.China;Cancer Hospital,Chinese Academy of Medical Sciences,Beijing 100009,China)

机构地区：[1]哈尔滨医科大学附属第二医院,黑龙江哈尔滨150000 [2]中国医学科学院肿瘤医院,北京100009

出　　处：《肿瘤学杂志》2019年第12期1031-1036,共6页Journal of Chinese Oncology

基　　金：国家重点研发计划“精准医学研究”项目(2016YFC0905300);哈尔滨医科大学研究生创新科研项目(YJSCX2017-63HYD)

摘　　要：自20世纪70年代流行病学调查显示非甾体抗炎类药物可以降低结直肠癌患病率和死亡率,随后研究发现环氧合酶-2(COX-2)是其作用靶点,COX-2受到抑制从而影响了结直肠癌的发生和发展,但机制一直不明确。随着研究不断深入,COX-2促结直肠癌增殖、抑制凋亡作用、促血管生成作用逐渐被报道。全文结合最新研究结果对COX-2与结直肠癌发生发展的关系以及相关治疗的进展做一综述,从而更好的理解COX-2在结直肠癌中的作用,并探讨以COX-2作为结直肠癌治疗靶标的可能。Since 1970 s,the epidemiological studies have demonstrated that non-steroidal anti-inflammatory drugs can reduce the incidence and mortality of colorectal cancer. Further studies confirmed that cyclooxygenase 2(COX-2) was the target of drug action,the inhibition of COX-2 would affect the occurrence and development of colorectal cancer,but the mechanism is still unclear. It has been reported that COX-2 promotes proliferation and inhibits apoptosis of colorectal cancer cells and enhances angiogenesis in cancer tissue. This article reviews the latest progress on the relationship between COX-2 and the development of colorectal cancer and the potential application of COX-2 as a therapeutic target for colorectal cancer.

关 键 词：环氧合酶-2 结直肠肿瘤 增殖 血管生成 耐药 

分 类 号：R735.34[医药卫生—肿瘤] R735.37[医药卫生—临床医学]